Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Palantir and bitcoin play MicroStrategy are expected to get a Nasdaq 100 index invite Friday. Will Moderna and Super Micro ...

Moderna Inc. closed $127.65 below its 52-week high ($170.47), which the company achieved on May 24th.

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

Army National Guard Specialist Karoline Stancik suffered three heart attacks and a stroke after receiving the Moderna ...

The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...

2024 has been a generally outstanding year for the stock market, with the S&P 500 ( ^GSPC 0.82%) up by nearly 30% year to ...

Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro ...